The firm's product revenues were up 19 percent year over year, while license and royalty revenues, as well as R&D, milestone, and grant revenues increased sharply.
The technology behind Mammoth's platform bears a striking resemblance to the CRISPR-based SHERLOCK platform developed by researchers at the Broad Institute.
The team paired the SHERLOCK platform developed in Feng Zhang's lab with a protocol that detects viruses directly from bodily fluids in less than two hours.
The company narrowed its net loss for Q4 2017 to $2.0 million, or $.16 per share, compared to a net loss of $2.6 million, or $.21 per share, in Q4 2016.
The latest version of the nucleic acid detection platform uses three CRISPR enzymes, making it more sensitive and capable of smaller quantitative measurements.
In a study looking at serum from Zika patients and those infected with related disease, the test showed 96 percent sensitivity and 96 percent specificity.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
Designed to run on the company's Sentosa real-time PCR system, the test has been approved for identifying and differentiating Zika in patients.
Chembio's point-of-care DPP Zika System, including an IgM/IgG assay and micro reader, provides quantitative results in 15 minutes from 10μl of fingertip blood.
The test is intended for use by blood collection facilities and is not approved for the individual diagnosis of Zika infection.